Should I buy or sell Exscientia stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAI shares. View EXAI analyst ratings or view top-rated stocks .

What is Exscientia's stock price target for 2024?

4 Wall Street research analysts have issued 1-year price targets for Exscientia's stock. Their EXAI share price targets range from $7.00 to $13.00. On average, they anticipate the company's stock price to reach $9.75 in the next year. This suggests a possible upside of 123.6% from the stock's current price. View analysts price targets for EXAI or view top-rated stocks among Wall Street analysts .

How have EXAI shares performed in 2024?

Exscientia's stock was trading at $6.41 at the start of the year. Since then, EXAI shares have decreased by 32.0% and is now trading at $4.36. View the best growth stocks for 2024 here .

When is Exscientia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our EXAI earnings forecast .

How were Exscientia's earnings last quarter?

Exscientia plc (NASDAQ:EXAI) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $41.63 million. Exscientia had a negative trailing twelve-month return on equity of 36.44% and a negative net margin of 737.10%.

What ETFs hold Exscientia's stock?

ETFs with the largest weight of Exscientia (NASDAQ:EXAI) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . First Trust Nasdaq Artificial Intelligence and Robotics ETF (ROBT) .

When did Exscientia IPO?

Exscientia (EXAI) raised $291 million in an IPO on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share.

Who are Exscientia's major shareholders?

Exscientia's stock is owned by a number of institutional and retail investors. Top institutional investors include GAMMA Investing LLC (0.00%).

How do I buy shares of Exscientia?

Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EXAI

Exscientia (EXAI) Stock Price, News & Analysis

→ Nvidia Has a BIG Problem — Here’s Who Benefits MOST (From Weiss Ratings) (Ad)

Free EXAI Stock Alerts

$4.38

+0.06 (+1.39%)

(As of 02:51 PM ET)

Compare

Today's Range: $4.27
▼
$4.49
50-Day Range: $4.25
▼
$7.51
52-Week Range: $4.17
▼
$9.12

Volume: 273,552 shs
Average Volume: 718,279 shs
Market Capitalization: $529.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.75

Get Exscientia alerts:

Exscientia MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 123.6% Upside
$9.75 Price Target
Short Interest: Bearish
3.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.52
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.76) to ($1.70) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.29 out of 5 stars

Medical Sector

780th out of 914 stocks

Biological Products, Except Diagnostic Industry

131st out of 151 stocks

3.3

Analyst's Opinion

Consensus Rating
Exscientia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Exscientia has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.70% of the float of Exscientia has been sold short.
Short Interest Ratio / Days to Cover
Exscientia has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Exscientia has recently increased by 15.65%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Exscientia does not currently pay a dividend.
Dividend Growth
Exscientia does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EXAI.

1.4

News and Social Media Coverage

News Sentiment
Exscientia has a news sentiment score of -0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Exscientia this week, compared to 2 articles on an average week.
Search Interest
Only 18 people have searched for EXAI on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.
MarketBeat Follows
32 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exscientia insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.40% of the stock of Exscientia is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
41.58% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Exscientia are expected to grow in the coming year, from ($1.76) to ($1.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exscientia is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exscientia is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exscientia has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

This Little-Known Stock Controls the Future of AI

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

If You Missed Out On The AI Boom, Take These 3 Steps

About Exscientia Stock (NASDAQ:EXAI)

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

EXAI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EXAI Stock News Headlines

April 18, 2024 | americanbankingnews.com

Exscientia (NASDAQ:EXAI) Sets New 52-Week Low at $4.17

April 16, 2024 | finance.yahoo.com

Exscientia plc (EXAI) Interactive Stock Chart - Yahoo Finance

April 18, 2024 | Weiss Ratings (Ad)

This Little-Known Stock Controls the Future of AI

March 23, 2024 | seekingalpha.com

Exscientia plc (EXAI) Q4 2023 Earnings Call Transcript

March 21, 2024 | investorplace.com

EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q4 2023

March 21, 2024 | businesswire.com

Exscientia Business and Financial Update for the Full Year 2023

March 19, 2024 | finance.yahoo.com

Exscientia plc's (NASDAQ:EXAI) market cap touched US$797m last week, benefiting both individual investors who own 48% as well as institutions

March 14, 2024 | ca.finance.yahoo.com

EXAI Jul 2024 10.000 put

April 18, 2024 | Weiss Ratings (Ad)

This Little-Known Stock Controls the Future of AI

March 14, 2024 | ca.finance.yahoo.com

EXAI May 2024 2.500 put

March 14, 2024 | ca.finance.yahoo.com

EXAI Jul 2024 2.500 call

March 14, 2024 | businesswire.com

Exscientia to Report Full Year 2023 Financial Results on March 21, 2024

March 11, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAI

March 4, 2024 | investorplace.com

The Top 3 Healthcare Stocks to Buy on Weakness in 2024

March 3, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAI

March 1, 2024 | msn.com

SHAREHOLDER ALERT: Potential Recovery for Exscientia plc (EXAI) Investors

February 28, 2024 | businesswire.com

Exscientia to Present at Upcoming Investor Conferences in March

February 26, 2024 | businesswire.com

Exscientia plc (EXAI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

February 24, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAI

February 23, 2024 | finance.yahoo.com

EXAI May 2024 17.500 call

February 23, 2024 | fool.com

Exscientia Plc (NASDAQ: EXAI)

February 17, 2024 | markets.businessinsider.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAI

February 15, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exscientia plc - EXAI

February 14, 2024 | msn.com

Oxford drug company sacks chief executive over ‘inappropriate’ relationships with staff

February 13, 2024 | msn.com

Exscientia CEO terminated from position due to inappropriate conduct - filing

February 13, 2024 | msn.com

AI Drug Hunter Firm Exscientia Fires Its CEO Over 'Inappropriate' Relationships with Two Employees

February 13, 2024 | reuters.com

Exscientia fires CEO after probe over relationship with two employees

See More Headlines

Receive EXAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:EXAI
CUSIP: N/A
CIK: 1865408
Web: www.exscientia.ai
Phone: 44-0-18-6581-8941
Fax: N/A
Employees: 483
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.75
High Stock Price Target: $13.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +125.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-181,560,000.00
Net Margins: -737.10%
Pretax Margin: -807.26%
Return on Equity: -36.44%
Return on Assets: -26.39%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 6.22
Quick Ratio: 6.22

Sales & Book Value

Annual Sales: $25.60 million
Price / Sales: 20.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.66 per share
Price / Book: 1.18

Miscellaneous

Outstanding Shares: 120,890,000
Free Float: 101,062,000
Market Cap: $522.24 million
Optionable: Optionable
Beta: 0.78

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. David Hallett Ph.D. (Age 55)
Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director
Mr. Ben R. Taylor (Age 47)
CFO, Chief Strategy Officer & Executive Director
Comp: $524.4k
Dr. Michael Krams M.D. (Age 63)
Chief Medical Officer
Ms. Eileen Jennings-Brown
Chief Information Officer
Ms. Sara Sherman
Vice President of Investor Relations
Mr. Dan Ireland
Vice President of Legal & Company Secretary
Mr. Parker Moss
Executive Vice President of Corporate Development
Ms. Caroline Rowland
Chief People Officer
Mr. Richard Law
Chief Business Officer
Dr. John P. Overington Ph.D.
Chief Data Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

EXAI Stock Analysis - Frequently Asked Questions

Should I buy or sell Exscientia stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EXAI shares.
View EXAI analyst ratings or view top-rated stocks.
What is Exscientia's stock price target for 2024?: 4 Wall Street research analysts have issued 1-year price targets for Exscientia's stock. Their EXAI share price targets range from $7.00 to $13.00. On average, they anticipate the company's stock price to reach $9.75 in the next year. This suggests a possible upside of 123.6% from the stock's current price.
View analysts price targets for EXAI or view top-rated stocks among Wall Street analysts.
How have EXAI shares performed in 2024?: Exscientia's stock was trading at $6.41 at the start of the year. Since then, EXAI shares have decreased by 32.0% and is now trading at $4.36.
View the best growth stocks for 2024 here.
When is Exscientia's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our EXAI earnings forecast.
How were Exscientia's earnings last quarter?: Exscientia plc (NASDAQ:EXAI) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $41.63 million. Exscientia had a negative trailing twelve-month return on equity of 36.44% and a negative net margin of 737.10%.

What ETFs hold Exscientia's stock?: ETFs with the largest weight of Exscientia (NASDAQ:EXAI) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).First Trust Nasdaq Artificial Intelligence and Robotics ETF (ROBT).
When did Exscientia IPO?: Exscientia (EXAI) raised $291 million in an IPO on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share.
Who are Exscientia's major shareholders?: Exscientia's stock is owned by a number of institutional and retail investors. Top institutional investors include GAMMA Investing LLC (0.00%).
How do I buy shares of Exscientia?: Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EXAI) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Exscientia (EXAI) Stock Price, News & Analysis

Exscientia MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Exscientia Stock (NASDAQ:EXAI)

EXAI Stock Price History

EXAI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

EXAI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™